Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus XHANCE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus XHANCE.
ASMANEX HFA vs XHANCE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
XHANCE (fluticasone propionate) is an anti-inflammatory corticosteroid that inhibits multiple inflammatory cell types and mediators (e.g., histamine, leukotrienes, cytokines) involved in nasal and sinus inflammation. It reduces nasal polyp size and nasal congestion.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
1 spray (93 mcg fluticasone propionate) per nostril twice daily (total daily dose 372 mcg). Intranasal route.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal half-life is approximately 2-3 hours; short half-life supports twice-daily dosing for sustained local effect.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% of the dose as unchanged drug; fecal excretion is minimal.
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid